Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Financing › Details

Nanoform–SEVERAL: investment, 201907 private placement €10m incl Ilmarinen Mutual Pension Insurance + Mandatum Life Insurance


Period Period 2019-07-03
Organisations Money taker Nanoform Finland Ltd.
  Group Nanoform (Group)
  Money source SEVERAL
Product Product nanonization™ technology

Nanoform Finland Ltd.. (7/3/19). "Press Release: Nanoform Continues Strategic Growth with €10 Million Private Placement". Helsinki.

Nanoform, an innovative medicine enabling nanotechnology company, announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.

The funding will be used to further develop Nanoform’s best-in-class nanonizationTM technology and strategically expand its ability to handle highly potent APIs. The investment will enable Nanoform to meet the growing demand for nanonized drug compounds with increased solubility and bioavailability.

The private placement follows the rapid construction of Nanoform’s first GMP manufacturing plant. Finalizing construction of this, and further building a second GMP facility, will help accelerate the development of more efficient therapies by significantly increasing the number of nanonized materials reaching clinical trials.

Albert Hæggström, CFO of Nanoform, said: “We are delighted with Mandatum Life Insurance Company’s additional investment in Nanoform and we sincerely welcome Ilmarinen Mutual Pension Insurance Company as a new shareholder. The completion of the private placement will enable us to add additional capacity to meet the growing demand we see from the market for enhanced APIs.”

Notes to the Editor

For further information, images and interview opportunities with Nanoform, please contact Lizzie Harrett at Notch Communications
+44 (0) 161 457 7230

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS??) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.

For more information please visit

Record changed: 2020-01-06


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Nanoform (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] No Content Marketing 650x80px

» top